Stock listing

Shanghai Henlius Biotech, Inc. Class H

Selected listing: 2696 · HKEX · HKD · HK

Shanghai Henlius Biotech, Inc. Class H (HKEX:2696), Health Technology. Latest release Sep 30, 2026: LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS.

2696:HKEXHKDHKUpdated October 2, 2026

Ticker: HKEX:2696
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: HKEX
Currency: HKD

About Shanghai Henlius Biotech, Inc. Class H

The company focuses on the development and commercialization of innovative biologics for the treatment of various diseases. Its commitment to advancing biopharmaceuticals positions it as a key player in the biotech industry.

Latest news from Shanghai Henlius Biotech, Inc. Class H

LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

September 30, 2026

(1) CHANGES IN NON-EXECUTIVE DIRECTOR AND INDEPENDENT NON-EXECUTIVE DIRECTOR (2) APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHANGES IN COMPOSITION OF THE BOARD COMMITTEES

September 30, 2026

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation

August 21, 2026

Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC

August 21, 2026

Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform

August 17, 2026

All Shanghai Henlius Biotech, Inc. Class H news →

Research Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. Class H company profile

View the public company page for Shanghai Henlius Biotech, Inc. Class H on 6ix.

Shanghai Henlius Biotech, Inc. Class H news

Read company news and market updates connected to Shanghai Henlius Biotech, Inc. Class H.

Shanghai Henlius Biotech, Inc. Class H investor events

Find investor webinars, events, and replay context for Shanghai Henlius Biotech, Inc. Class H.